Advanced BioDesign, founded in 2010 and based in Lyon, France, develops an innovative targeted therapy to treat resistant cancers with a first indication in acute myeloid leukemia (AML). Its main anti‑cancer compound, ABD‑3001, is a first‑in‑class suicide inhibitor of aldehyde dehydrogenases 1 & 3 (ALDH1 & ALDH3) that induces apoptosis in cancer cells while sparing healthy cells. ABD‑3001 is currently in the preclinical stage. The company plans to submit its regulatory file to the French National Agency for Medicines and Health Products Safety (ANSM) in 2020 and is preparing to enter Phase I clinical trials in early 2021. Advanced BioDesign intends to use the new funds for clinical development, finalization of preclinical studies, and submission of a clinical trial authorization for AML. The company is led by CEO Ismail Ceylan.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2020